In the original publication [1], there was a mistake in Figure 4C as published. During the preparation of the original manuscript, we regret having made a careless error by reproducing the experiment of Figure 3C in Figure 4C (EV vs. RP5-1024C24.1 in the FRO cell line) instead of showing the EV vs. MPPED2 experiment in the FRO cell line. We have made a correction by providing a new panel for Figure 4C in the FRO cell line by assembling the right images for EV and MPPED2. The corrected Figure 4C appears below. The authors apologize for any inconvenience caused and state that the scientific conclusions are unaffected. This correction was approved by the Academic Editor. The original publication has also been updated.
Footnotes
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.
Figure 4. MPPED2 negatively modulates cell proliferation and migration of thyroid carcinoma cell lines. (A) qRT-PCR analysis performed on TPC-1 and FRO cell lines stably carrying MPPED2 or the corresponding empty vector (EV). Values were reported as relative expression ± SEM and were compared to EV, set equal to 1. t-test; * p < 0.05 (left panel). Immunoblot analysis confirming the expression of MPPED2. GAPDH and β-Actin were used to normalize the amount of loaded protein (right panel). (B) Cell growth analysis of TPC-1 and FRO stably carrying MPPED2 or EV. Cell number was evaluated at 24 h, 48 h, 72 h and 96 h after seeding. Values were obtained from three independent experiments performed in duplicate and data were reported as mean ± SEM. 2-way Anova-test followed by Bonferroni post-test; * p < 0.05; *** p < 0.001. (C) Representative colony assay performed on TPC-1 and FRO cell lines stably carrying MPPED2 or EV. (D) Representative cell cycle analysis of TPC-1-MPPED2 and TPC-1-EV cells. Cell number was reported on the y-axis while the percentage of propidium iodide (PI) incorporated was reported on the x-axis (left panel). Values shown in the right panel were obtained from three independent experiments. t-test; * p < 0.05 compared to EV. (E) Representative acquisition of migration assays performed on MPPED2 or EV transfected TPC-1 and FRO cells (magnification 40×) (left panel). Values obtained from three (TPC-1) or four (FRO) independent experiments were reported as mean ± SEM and compared to the EV, set equal to 1 (right panel). t-test; * p < 0.05. (F) qRT-PCR analysis to evaluate the expression of RP5-1024C24.1 after MPPED2 transfection. Data obtained from three (TPC-1) or five (FRO) independent experiments were reported as relative expression ± SEM and were compared to the EV, set equal to 1. t-test; p = ns.
Reference
1. Sepe, R.; Pellecchia, S.; Serra, P.; D’Angelo, D.; Federico, A.; Raia, M.; Cortez Cardoso Penha, R.; Decaussin-Petrucci, M.; Del Vecchio, L.; Fusco, A. et al. The Long Non-Coding RNA RP5-1024C24.1 and Its Associated-Gene MPPED2 Are Down-Regulated in Human Thyroid Neoplasias and Act as Tumour Suppressors. Cancers; 2018; 10, 146. [DOI: https://dx.doi.org/10.3390/cancers10050146] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/29783666]
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
Details




1 Institute of Experimental Endocrinology and Oncology (IEOS) “G. Salvatore”, National Research Council (CNR), Via Sergio Pansini 5, 80131 Naples, Italy;
2 Service d’Anatomie et Cytologie Pathologiques, Centre de Biologie Sud, Groupement Hospitalier Lyon Sud, 69495 Pierre Bénite, France
3 Department of Molecular Medicine and Medical Biotechnology (DMMBM), University of Naples “Federico II”, Via Sergio Pansini 5, 80131 Naples, Italy; CEINGE-Biotecnologie Avanzate, Via Gaetano Salvatore 486, 80145 Naples, Italy
4 Institute of Experimental Endocrinology and Oncology (IEOS) “G. Salvatore”, National Research Council (CNR), Via Sergio Pansini 5, 80131 Naples, Italy;